Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03400163 · ClinicalTrials.gov registry record · Phase 2
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03400163 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 3 participants.
The verdict
NCT03400163, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)
Interventions
- DRUG Placebo
- DRUG BMS-986036
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-05-08 |
| Est. Completion | 2017-06-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03400163
The ClinicalTrials.gov registry entry for NCT03400163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03400163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03400163 about?
NCT03400163 is a clinical study titled "A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)". The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)
What is the current status of trial NCT03400163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2015-05-08. Estimated completion is 2017-06-19.
What interventions are being tested in trial NCT03400163?
The interventions under investigation include: Placebo (DRUG), BMS-986036 (DRUG).
Who is sponsoring clinical trial NCT03400163?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.